Dorothy Brach

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Dorothy Brach, Danielle Johnston-Blackwell, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 70 citations

Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation

Michael J. Thomenius, Jennifer Totman, Darren M. Harvey et al. · PLoS ONE · 2018 · 55 citations · Full text

Small Molecule Inhibitors, Engineering, Molecular Biology +19

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies

John W. Lampe, Joshua S. Alford, P. Ann Boriak-Sjodin et al. · ACS Medicinal Chemistry Letters · 2021 · 33 citations · Full text

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Joshua S. Alford, John W. Lampe, Dorothy Brach et al. · ACS Medicinal Chemistry Letters · 2022 · 32 citations · Full text